Area of research
Psychiatry and Mental health · Physiology
Research interest
Research interests include Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, Functional Brain Connectivity Studies, and Health, Environment, Cognitive Aging.
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Revised criteria for the diagnosis and staging of Alzheimer’s disease
The mediating role of neuroimaging-derived biological brain age in the association between risk factors for dementia and cognitive decline in middle-aged and older individuals without cognitive impairment: a cohort study
Dementia prevention in memory clinics: recommendations from the European task force for brain health services
Astrocyte biomarkers GFAP and YKL‐40 mediate early Alzheimer's disease progression
Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients
Where is VALDO? VAscular Lesions Detection and segmentatiOn challenge at MICCAI 2021
Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer’s continuum
The Open-Access European Prevention of Alzheimer’s Dementia (EPAD) MRI dataset and processing workflow
Association of Self-reflection With Cognition and Brain Health in Cognitively Unimpaired Older Adults
Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services—part 4 of 6
Dementia risk communication. A user manual for Brain Health Services—part 3 of 6
Characteristics of subjective cognitive decline associated with amyloid positivity
A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images
CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study
UCL Discovery (University College London) 2021cited by 48position: middle
The characterisation of subjective cognitive decline
World‐Wide FINGERS Network: A global approach to risk reduction and prevention of dementia
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected
Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's <i>continuum</i>
Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics
Drug repositioning and repurposing for Alzheimer disease
Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease‐modifying therapies
Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset
The European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study: Baseline Data Release V500.0
FLAME: A computerized neuropsychological composite for trials in early dementia
The relation between APOE genotype and cerebral microbleeds in cognitively unimpaired middle- and old-aged individuals